Apr. 1, 2013 ? A team of international cancer researchers led by Dr. Mathieu Lupien at the Princess Margaret Cancer Centre, University Health Network, has identified the signalling pathway that is over-activated in estrogen receptor (ER)-positive breast cancer cells that are resistant to hormone therapies such as tamoxifen, aromatase inhibitors or fulvestrant.
Resistance to hormone therapy is reported in almost half of ER-positive breast cancer patients and no cure is currently available. The fact that the pathway, called Notch, is a drug target creates hope for a new therapy.
The findings, published online today in the Proceedings of the National Academy of Sciences, "provide a new therapeutic target against hormone therapy-resistant breast cancers and a companion test to identify tumours that would become resistant" says Dr. Lupien, a scientist at the Ontario Cancer Institute, the research arm of the cancer centre, and an Assistant Professor in the Department of Medial Biophysics, University of Toronto. He specializes in epigenetics of hormone-dependent cancers -- the study of non-genetic determinants of cellular identity that can also be altered to initiate or modify disease.
"In studying the epigenetics of hormone therapy resistance, we discovered that breast cancer cells behave like a chameleon. Indeed, as the chameleon changes its skin colour to camouflage itself and evade predators," says Dr. Lupien, "breast cancer cells change the appearance of their DNA through epigenetics to evade, in this case, hormone therapy." In so doing, hormone therapy-resistant breast cancer cells highlight regions of their DNA related to the Notch pathway.
At the molecular level, the research team characterized the epigenetic appearances of the DNA of drug-resistant and drug-responsive breast cancer cells. The team discovered that the Notch signaling pathway plays the predominant role in drug-resistant breast cancer cells even if cells remain positive for ER.
"This is a highly promising discovery that could rapidly translate in the clinic. Drugs against the Notch pathway are available." says Dr. Lupien. The key will be to test the efficacy of these drugs against hormone therapy resistance in breast cancer.
The research was funded by the National Cancer Institute, the American Cancer Society and the Ontario Institute for Cancer Research. Dr. Lupien's research is also supported by The Princess Margaret Cancer Foundation.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by University Health Network.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- Luca Magnani, Alexander Stoeck, Xiaoyang Zhang, Andr?s L?nczky, Anne C. Mirabella, Tian-Li Wang, Bal?zs Gyorffy, and Mathieu Lupien. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proceedings of the National Academy of Sciences, 2013; DOI: 10.1073/pnas.1219992110
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
Source: http://feeds.sciencedaily.com/~r/sciencedaily/health_medicine/genes/~3/pUzj0i7pl44/130401151035.htm
punksatony phil 2012 groundhog day groundhog phil pee wee herman ketamine ground hogs day 2012 goundhog day
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন